Tricaprilin Liquid Formulation PK Study
A Phase 1, Three-part, Part-randomised, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Different Formulations of Tricaprilin, to Include Single-dose, Food Effect, and Titration Tolerability, in Healthy Participants
Sponsor: Cerecin
Terminated
Part 1 was completed, Part 2 and Part 3 of the study were not conducted under this study protocol due to subject recruitment difficulty.
This PHASE1 trial investigates Alzheimer Disease and is currently terminated or withdrawn. Cerecin leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
-
Oct 2023 — Nov 2023 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Nov 2021 — Oct 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cerecin
For direct contact, visit the study record on ClinicalTrials.gov .